CTOR vs NIVF
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Oct 04, 2026
CTOR
36.9
AI Score
VS
NIVF Wins
NIVF
50.4
AI Score
Investment Advisor Scores
NIVF
50score
Recommendation
HOLD
AI Analyst Insights
AI insights temporarily unavailable
Detailed Metrics Comparison
| Metric | CTOR | NIVF | Winner |
|---|---|---|---|
| Revenue | 7.11M | 4.73M | CTOR |
| Net Income | -41.07M | 9.88M | NIVF |
| Gross Margin | 77.3% | 20.2% | CTOR |
| Net Margin | -578.0% | 209.0% | NIVF |
| Operating Income | -42.58M | -10.73M | NIVF |
| ROE | -101.7% | 37.1% | NIVF |
| ROA | -36.6% | 30.2% | NIVF |
| Total Assets | 112.09M | 32.72M | CTOR |
| Cash | 16.56M | 758,621 | CTOR |
| Current Ratio | 0.73 | 3.12 | NIVF |
Relative Price Performance (Last 90 Days)
CTOR 1M: +22.2%
· 3M: +34.0%
NIVF 1M: -89.3%
· 3M: -91.3%
Current Technical Phase
CTOR
MarkupHold / add on dips
Price above SMA50, rising 50-day trend (18.4% over 20 days), RSI 51
NIVF
MarkdownSell / avoid
Price below a falling SMA50 (slope -19.7%), weak momentum, RSI 31
Fundamentals Snapshot
| Metric | CTOR | NIVF |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | 9.5 | 0.0 |
| Trailing P/E | — | 0.0 |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.0% | 0.1% |
| Gross Margin | 0.7% | 0.2% |
| Operating Margin | -6.0% | -3.5% |
| EPS | -0.47 | 197.38 |
| Dividend Yield | — | — |
Frequently Asked Questions
Based on our detailed analysis, NIVF is currently the stronger investment candidate, winning 6 of the key financial metrics based on our comprehensive scoring model.
We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.
Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.